Last reviewed · How we verify

brand name metoprolol ER

University of Florida · FDA-approved active Small molecule

Metoprolol ER is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of norepinephrine and epinephrine on the heart.

Metoprolol ER is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of norepinephrine and epinephrine on the heart. Used for Hypertension, Angina pectoris, Myocardial infarction (post-MI management).

At a glance

Generic namebrand name metoprolol ER
Also known asMetoprolol extended-release (ER)
SponsorUniversity of Florida
Drug classBeta-1 selective adrenergic receptor antagonist (beta-blocker)
TargetBeta-1 adrenergic receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Metoprolol selectively blocks beta-1 adrenergic receptors on cardiac tissue, decreasing heart contractility and heart rate. This reduces myocardial oxygen demand and lowers blood pressure. The extended-release formulation provides sustained drug delivery over 24 hours, allowing once-daily dosing for improved patient compliance in chronic cardiovascular conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: